Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $26.71
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have earned an average recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock […]
More Stories
Explainer: How UN peacekeepers meet the challenge of escalating conflict in Lebanon
The UN peacekeeping mission UNIFIL has been operating along the “Blue Line” which separates Lebanon and Israel since the 1970s,...
Israel: New law blocking UNRWA ‘would be a catastrophe’, Guterres warns
Two bills before the Israeli parliament could put a halt to the lifesaving operations of UN Palestine relief agency, UNRWA,...
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40
LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research...
Analysts Set Spirax-Sarco Engineering plc (LON:SPX) Price Target at GBX 9,158
Spirax-Sarco Engineering plc (LON:SPX – Get Free Report) has been given an average rating of “Reduce” by the eight ratings...
Markel Group Inc. (NYSE:MKL) Receives $1,626.83 Average Target Price from Analysts
Markel Group Inc. (NYSE:MKL – Get Free Report) has been assigned an average recommendation of “Hold” from the six brokerages...
UWM Holdings Co. (NYSE:UWMC) Given Consensus Rating of “Reduce” by Analysts
UWM Holdings Co. (NYSE:UWMC – Get Free Report) has been given a consensus recommendation of “Reduce” by the seven research...